Pliant Therapeutics (PLRX)

• Market cap: $91.9M
• 1 day: 1.35%
• 5 days: 5.63%
• 1 month: -5.66%
• 3 months: -86.26%
• 6 months: -89.75%
• Year to date: -88.70%
• 1 year: -88.10%
• 5 years: -92.96%
• 10 years: -92.96%
• Sector: Healthcare
• Industry: Biotechnology

About: Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Employees: 171

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

77% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 13

28% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 43

20% more funds holding in top 10

Funds holding in top 10: 5 [Q3] → 6 (+1) [Q4]

18% more capital invested

Capital invested by funds: $725M [Q3] → $853M (+$127M) [Q4]

6% more funds holding

Funds holding: 151 [Q3] → 160 (+9) [Q4]

1.99% more ownership

Funds ownership: 104.43% [Q3] → 106.42% (+1.99%) [Q4]

88% less call options, than puts

Call options by funds: $1.27M | Put options by funds: $10.7M

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1.50 0% upside
• Avg. target: $3.92 161% upside
• High target: $10 567% upside

6 analyst ratings

• positive: 0 0%
• neutral: 6 100%
• negative: 0 0%

Citigroup David Lebowitz 42% 1-year accuracy 8 / 19 met price target	0% upside $1.50	Neutral Maintained	4 Mar 2025
RBC Capital Brian Abrahams 6% 1-year accuracy 4 / 68 met price target	100% upside $3	Sector Perform Maintained	4 Mar 2025
Wells Fargo Tiago Fauth 30% 1-year accuracy 8 / 27 met price target	100% upside $3	Equal-Weight Maintained	4 Mar 2025
Needham Joseph Stringer 22% 1-year accuracy 26 / 118 met price target	567% upside $10	Hold Downgraded	4 Mar 2025
Leerink Partners Faisal Khurshid 15% 1-year accuracy 2 / 13 met price target	33% upside $2	Market Perform Downgraded	3 Mar 2025